Resources

A new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute provides the latest evidence that biosimilar competition is saving patients billions – and additional competition would increase savings even more. Click to download the brief From 2019-2023, patients saved $15 billion from biosimilar competition.  Had there been competition during the same period for two other biologics, Humira and Enbrel, patients would have saved another $13 billion, for a total of $28 billion. “The growing...

SACRAMENTO – A new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute analyzes a Journal of the American Medical Association (JAMA) study cited by Sen. Bernie Sanders (I-Vermont) to justify drug price controls, finding it was deeply flawed and would put patients at risk of losing access to cutting-edge medications if implemented. Click to download “Sen. Sanders uses a flawed analysis to promote price controls on innovative drugs, which would  jeopardize the health...

The current federal regulatory process to develop monoclonal antibodies to treat mutating strains of COVID-19 imposes unnecessary hurdles that hinder the creation and approval of effective treatments for the immunocompromised, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute. Click to download the brief “Monoclonal antibodies provided benefits to vulnerable populations and six different ones were authorized to treat COVID-19,” said Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics...

SACRAMENTO – Fixing the current broken system that incentivizes pharmacy benefit managers (PBMs) to enact policies that benefit themselves and insurers at the expense of patients would lead to lower patient drug costs, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute. Click to download the brief “The current system incentivizes PBMs to implement policies that benefit insurers and themselves, while making drugs less affordable and available,” said Dr. Wayne Winegarden,...

Listen to Dr. Wayne Winegarden, PRI senior fellow in business and economics and director of PRI's Center for Medical Economics and Innovation, discuss his new brief "No Solutions, Only Tradeoffs," which explores how the small health benefits generated by state COVID-19 lockdowns were more than offset by huge losses in education and the economy. TheLarsLarsonShow · Dr Wayne Winegarden Did Covid Restrictions Wreck Our Economy For Nothing...

SACRAMENTO – States that had more invasive COVID-19 restrictions saw small reductions in COVID-19 infection and mortality rates, but saw large negative impacts on employment, economic growth, and children’s education outcomes, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute. Click to download the brief “Looking at the data, states with stricter COVID-19 public health policies did see small health benefits from reduced infections and mortality rates – but at the...

Watch as the Professor buys a bike for Penny to show how the broken health care payment system hurts Medicare patients. They explore that by creating a support program based on income, we can help Medicare patients buy private insurance instead of being stuck with poor government care. READ THE STUDY   https://www.youtube.com/watch?v=rvlwyvVGcNY...

Watch as Penny is unhappy that she has to enter the geography bee instead of the science fair due to bureaucratic rules at school. The Professor explores how, much in the same way, eliminating unnecessary barriers can produce a more efficient and productive health care system. To learn more, read the Coverage Denied series at www.medecon.org   https://www.youtube.com/watch?v=RmLoJWQ935M...

Providing cash-based support to the vulnerable to purchase private health insurance would increase access to quality healthcare at roughly the same per enrollee costs as Medicaid programs - finds the latest paper in the Coverage Denied series released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute. Click to download the brief “Tens of millions are stuck in a flawed government-run healthcare system that provides sub-par care to patients, imposes huge taxpayer costs, and harms the...

DOWNLOAD THE BRIEF   Executive Summary Declining productivity growth in the delivery of healthcare is not innate to the sector. It simply reflects the current policy environment. Incentivizing a more productive and cost-effective healthcare provider sector is possible but requires comprehensive policy reforms that eliminate the obstacles blocking progress. These reforms include: Implementing the insurance reforms discussed in Part 5 that, from a provider perspective, will incentivize the creation of innovative payment models. New payment models create opportunities to better align the incentives...

SACRAMENTO – The broken 340B program, designed to provide affordable care for at-risk patients, creates massive profits for providers without necessarily improving patient health outcomes and should be reformed, finds a new issue brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute. Click here to download a copy of the brief “The 340B program is growing unsustainably and isn’t improving health outcomes for at-risk patients,” said Dr. Wayne Winegarden, the Center’s director and the...

CLICK HERE TO READ THE BRIEF In addition to the reforms to the health insurance system, which will help address the problems of drug affordability, reforms tailored to the pharmaceutical sector are necessary. These reforms should eliminate drug supply chain inefficiencies and include: fostering a patient-controlled generics market, creating price transparency through reforms that ensure patients directly benefit from all discounts when purchasing their medicines,  fixing the drug formularies’ systemic biases against low-cost medicines, and encouraging contracting innovations that could create...

SACRAMENTO – Biosimilars competition saves patients and the health care system over $11 billion annually and could generate even more savings if the broken drug pricing system were reformed, finds a new issue brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute. “Patients living with cancer, autoimmune diseases, osteoporosis, and other illnesses are receiving revolutionary treatment from biologics,” said Dr. Wayne Winegarden, the Center director and the study’s author. “As our research shows,...

CLICK HERE TO READ THE BRIEF Establishing an Efficient Health Insurance Market Cultivating an efficient health insurance market requires reforms that empower patients over payers, which can be achieved by: Making health expenditures and health insurance expenditures tax deductible;  Broadening the availability and usability of tax-free saving accounts to help patients cover the deductibles and out of pocket expenses that could arise should they require costly healthcare services; and Promoting price transparency and insurance competition to enable a more competitive pro-patient healthcare...

Listen to the author of a new study discuss how America’s broken third-party healthcare payment system prioritizes government and insurance companies as the largest payers, leaving patients with higher out-of-pocket costs, greater exposure to healthcare financial risk, and reduced access to care.  To learn more, read the "Coverage Denied" series from PRI's Center for Medical Economics and Innovation. ...